- Earns ESG Risk Rating score of 9.0, ranking among the top 0.5% in the pharmaceuticals industry

- Advances from 'Low Risk' to 'Negligible Risk,' the lowest ESG risk category

- Recognition reflects continued improvements in ESG risk management across operations

INCHEON, South Korea, Nov. 3, 2026 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organization (CDMO), has achieved a 'Negligible Risk' rating in the latest Morningstar Sustainalytics ESG Risk Ratings assessment, marking further progress in its environmental, social, and governance (ESG) performance.

Samsung Biologics received an ESG Risk Rating score of 9.0, advancing from its previous 'Low Risk' rating to 'Negligible Risk,' the lowest of five risk categories. The result places the company among the top 0.5% of companies assessed in the pharmaceuticals industry.

Morningstar Sustainalytics, an independent ESG research and ratings provider, assesses approximately 16,000 companies worldwide based on their exposure to material ESG risks and how effectively those risks are managed. Under its methodology, scores below 10 indicate a negligible level of unmanaged ESG risk, with lower scores reflecting lower overall risk.

The improved rating reflects Samsung Biologics' continued efforts to strengthen ESG management across its business. The company has implemented initiatives to enhance environmental auditing, occupational health and safety, quality management, and business ethics, while reinforcing internal processes and oversight to identify and address potential risks.

"Effective risk management is fundamental to how we operate as a global CDMO," said John Rim, President and CEO of Samsung Biologics. "This recognition demonstrates the progress we have made in embedding responsible practices across our business. As we expand our global operations, we will continue to take a disciplined approach to managing risks and maintaining the trust of our clients and stakeholders."

The achievement follows Samsung Biologics' recent 'A' rating in the 2026 MSCI ESG Ratings assessment. Earlier this year, the company also received the EcoVadis Platinum Sustainability Rating, placing it among the top 1% of companies assessed globally.

About Samsung Biologics Co., Ltd.

Samsung Biologics Co., Ltd., Incheon, Republic of Korea (KRX: 207940.KS) is a leading contract development and manufacturing organization (CDMO), offering end-to-end integrated services that range from late discovery to commercial manufacturing.

With a combined biomanufacturing capacity of 785,000 liters across Bio Campus I and II in Korea, and 60,000 from the manufacturing facility in Rockville, Maryland, U.S., Samsung Biologics holds total global manufacturing capacity of 845,000 liters. Samsung Biologics has also secured land for Bio Campus III, laying the groundwork for future capacity expansion to support next-generation therapies and emerging modalities.

Samsung Biologics leverages cutting-edge technologies and expertise to advance diverse modalities, including multispecific antibodies, fusion proteins, antibody-drug conjugates, and mRNA therapeutics.

By implementing the ExellenS⢠framework across its manufacturing network with standardized designs, unified processes, and advanced digitalization, Samsung Biologics ensures plant equivalency and speed for manufacturing continuity.

Samsung Biologics' global manufacturing and commercial network spans Korea, the U.S., Europe, and Japan. Samsung Biologics continues to invest in new capabilities to maximize operational and quality excellence, ensuring flexibility and agility for clients. Samsung Biologics is committed to the on-time, in-full delivery of safe, high-quality biomedicines, as well as to making sustainable business decisions for the betterment of society and global health. For more information, please visit https://samsungbiologics.com.

Media contacts

Claire Kim, Senior Director cair.kim@samsung.com 

Becky Lee, Director brite.lee@samsung.com

SOURCE Samsung Biologics

Share this article

SynKIRâ¢-110 demonstrated faster tumor control with approximately 10-fold lower IFNγ and 30-fold lower TNFα and IL-2 production compared to CD28-based single-chain CAR T in preclinical models

Preclinical in vivo data showed reduced exhaustion of tumor-infiltrating SynKIRâ¢-110 T cells and no accumulation in healthy lung tissue compared to conventional single-chain CAR T designs

In vitro data showed reductions in T cell exhaustion, off-target proliferation, and toxicity with SynKIRâ¢-110

PHILADELPHIA, Nov. 3, 2026 /PRNewswire/ -- Verismo Therapeutics, a clinical-stage CAR T cell therapy company pioneering a novel multi-chain KIR-CAR platform technology, today announced new preclinical data demonstrating enhanced anti-tumor activity, reduced cytokine release, and lower T cell exhaustion with SynKIRâ¢-110 with reduced off-target activity compared to conventional single-chain CAR T designs. The data will be presented at the Society for Immunotherapy of Cancer (SITC) 41st Annual Meeting in Phoenix, Arizona (Abstract 253). The study evaluated SynKIRâ¢-110 against CD28- and 4-1BB-based single-chain CAR T cells in preclinical mesothelioma xenograft models.

Poster Presentation Details

Title: Mesothelin-targeted Multi-Chain Killer Immunoglobulin Receptor (KIR)-based CAR T Reduces Exhaustion, Cytokine Release, and Enhances Safety Profile in vivo vs CD28 or 41BB single-chain CAR T

Presenter: Nora Yucel, Ph.D., Verismo Therapeutics

Session: Cellular Therapies â Chimeric Antigen Receptors

Session Date and Time: Friday, November 6, 2026 â 10 a.m.â2 p.m., 5â7 p.m. MT

Abstract Number: 253

Location: Phoenix Convention Center, Phoenix, Arizona

Full Abstract: https://www.sitcancer.org/2026/abstracts/titles-and-publications

In head-to-head comparisons, SynKIRâ¢-110 achieved the fastest tumor control among the three CAR T designs with low cytokine production, while CD28-based single-chain CAR T cells produced approximately 10-fold higher IFNγ and 30-fold higher TNFα and IL-2 levels. Tumor-infiltrating SynKIRâ¢-110 CD8 T cells also demonstrated reduced expression of exhaustion markers TIM3, LAG3, and PD1 compared to both single-chain comparators. Additionally, while both single-chain CAR T groups showed off-target activity in vitro and accumulation of CD8 CAR T cells in healthy lung tissue in vivo, no such effects were observed in SynKIRâ¢-110-treated animals.

"These preclinical head-to-head findings reinforce the mechanistic rationale behind the multi-chain KIR-CAR platform â that separating antigen binding from T cell activation can meaningfully reduce tonic signaling and non-specific off-target activity associated with conventional single-chain CAR T designs, without compromising antitumor control," said Laura Johnson, Ph.D., Chief Scientific Officer and Chief Operating Officer of Verismo Therapeutics. "Seeing SynKIRâ¢-110 deliver the fastest tumor control among the three CAR T architectures tested, with substantially lower cytokine production versus CD28-based single-chain CAR T, reduced T cell exhaustion markers compared with both single-chain comparators, and no off-target accumulation in healthy lung tissue, supports the differentiated safety and efficacy profile we are now evaluating in the ongoing STAR-101 clinical trial in patients with mesothelin-expressing solid tumors."

SynKIRâ¢-110 is currently being evaluated in the ongoing Phase 1 STAR-101 clinical trial (NCT05568680) in patients with advanced mesothelin-expressing solid tumors, including mesothelioma, ovarian cancer, and cholangiocarcinoma. Initial clinical data presented at AACR 2026 showed a favorable safety profile in nine patients across the first three dose-escalation cohorts, with no dose-limiting toxicities, no Grade 3 or higher cytokine release syndrome, and no immune effector cell-associated neurotoxicity syndrome (ICANS) observed, while also demonstrating tumor reduction. SynKIRâ¢-110 has received Orphan Drug and Fast Track designations from the U.S. Food and Drug Administration for mesothelioma. Dose escalation remains ongoing to determine the recommended Phase 2 dose.

About the KIR-CAR Platform

The KIR-CAR platform is a multi-chain T cell therapy that has shown highly effective solid tumor treatment in otherwise CAR-resistant animal models with hard-to-treat tumors. Using NK cell-derived killer immunoglobulin-like receptor (KIR) and DAP12 to split the target binding and T cell activation signals provides a novel paired immune-receptor activation that is independent from CD3 signaling and does not require additional co-stimulation. KIR-CAR enables sustained cell receptor expression in T cells, and induces deeper, more durable tumor treatments. Together, this multi-chain cell signaling platform provides the potential to deliver effective patient treatments by minimizing the background activation and early T cell exhaustion observed in conventional single-chain CAR T therapy, with potential to treat patients with both solid and hematologic tumors.

About Verismo Therapeutics

Verismo Therapeutics, a subsidiary of HLB Innovation, is a pioneer in multi-chain KIR-CAR technology, with assets SynKIRâ¢-110 (NCT05568680) and SynKIRâ¢-310 (NCT06544265) currently in Phase 1 clinical trials. Verismo is the only company developing the KIR-CAR platform, using a modified NK cell-derived receptor and DAP12 pairing, designed to improve T cell functional persistence and reduce exhaustion, resulting in improved efficacy against challenging tumors. The KIR-CAR platform technology was specifically developed to address areas of high unmet medical need, including advanced solid tumors and B cell-associated disorders and malignancies. For more information, visit: www.verismotherapeutics.com

Forward Looking Statements

This press release contains forward-looking statements, including, but are not limited to, those statements regarding our expectations for the timing, progress, and results of clinical trials; potential regulatory approvals; anticipated benefits, safety, and efficacy of our product candidates; our product development strategies; and other statements that are not historical facts. These forward-looking statements are based on our current expectations and are subject to numerous risks and uncertainties that could cause actual outcomes to differ materially. Important factors that could cause actual results to differ include, among others, risks related to clinical trials, regulatory processes, market acceptance, financial projections, and our ability to successfully develop and commercialize our product candidates. Forward-looking statements in this release represent our beliefs and assumptions only as of the date hereof, and we expressly disclaim any obligation to update these statements as new information becomes available, except as required by law.

Media Contact:

Peter Collins

TogoRun

p.collins@togorun.com

908-499-1200

Investor Relations:

Pavel Aprelev, Ph.D.

Verismo Therapeutics

Pavel.Aprelev@verismotherapeutics.com

SOURCE Verismo Therapeutics

Share this article

Less than a year after signing, the partnership has new American investment and a joint committee advancing Grand Inga

WASHINGTON, Nov. 3, 2026 /PRNewswire/ -- Less than a year after it was signed, the United States - Democratic Republic of Congo (DRC) Strategic Partnership Agreement is moving from concepts on paper to committed projects on the ground. The latest step came in Paris, where the two governments launched joint governance of Grand Inga, the Congo River hydropower complex that would be the largest in the world.

Signed in Washington back on December 4, 2025, the agreement covers investment, critical minerals, infrastructure and energy. Its Joint Steering Committee formally began implementation in February. In April, KoBold Metals, one of the largest American investors in the DRC, launched a $50 million lithium exploration program. In August, the DRC signed a 30-year, $1.26 billion concession to rebuild the 1,000-kilometer DR Congo link of the Lobito Corridor railway.

Grand Inga is where the partnership turns minerals into megawatts. The inaugural Grand Inga Coordination and Governance Committee met at the World Bank offices in Paris. It was co-chaired by Daniel Mukoko Samba, Deputy Prime Minister, and Jeremy Wiggins of the U.S. Department of the Treasury. The delegations focused on developing Grand Inga in coordinated phases.

"For decades, Inga was a promise. In Paris, we started running it as a project, and that is what this entire partnership is about," said Deputy Prime Minister Daniel Mukoko Samba. "Congo does not intend to remain a place where minerals are dug up and shipped out. We intend to process them here, with Congolese workers and Congolese power, and Grand Inga is how we get there."

Only about one in five Congolese has access to electricity, according to the World Bank, and without reliable power much of the copper and cobalt mined in the DRC leaves the country unprocessed. The Inga site holds an estimated 42,000 megawatts of potential power on a scale that could drive manufacturing, mineral processing, housing and additional infrastructure. That is nearly double the 22,500 megawatts installed at China's Three Gorges Dam, the world's largest operating power station. Inga 1 and Inga 2, about 1,800 megawatts combined, are in operation today.

"Americans hear a great deal about Congo's minerals. They should hear just as much about Congo's power," said Ambassador Yvette Kapinga Ngandu, Ambassador of the Democratic Republic of the Congo to the United States. "This partnership was never only about what comes out of the ground. A railroad, new American investment and now the Grand Inga hydropower complex show what it can build for American supply chains and for the Congolese families who still live without electricity."

During Inga's first phase, the project is expected to create 4,000 to 6,000 jobs, and projections estimate up to 8 million jobs as it develops. The project is a cornerstone of the DRC's goal to bring electricity to 62 percent of the population, about 82 million people, by 2030. The Grand Inga committee also placed environmental and social safeguards for affected communities on its agenda.

MEDIA CONTACT

Michael McManus | 88 Dragons PR Inc. |  202-215-9254  | michael.mcmanus@88dragonspr.com

This material is distributed by 88 Dragons PR Inc. on behalf of the Government of the Democratic Republic of the Congo. Additional information is available at the Department of Justice, Washington, DC.

SOURCE The Democratic Republic of Congo

Share this article

Small Joys, Big Market: Products That Spark Joy Take the Spotlight at 140th Canton Fair

GUANGZHOU, China, Nov. 3, 2026 /PRNewswire/ -- As emotional value becomes a key consumption driver, consumers are increasingly willing to pay for fun, companionship and peace of mind, offering an everyday interpretation of what "Better Life" truly means. This trend was on display throughout Phase 3 of the 140th Canton Fair.

Small Products, Big Feelings

In the Office Supplies Section, beyond traditional business supplies, vibrant products are capturing attention. Pens are expected to be visually appealing while staplers are designed to be cute as well as functional. Products that provide a burst of pleasure are gaining popularity.

3D stickers have emerged as a favorite among journaling enthusiasts. These stickers double as puzzles, requiring no glue and allowing users to assemble them for fun, turning decorations into interactive toys.

In the Toys Section, bag charms in various designs are ubiquitous. Meanwhile, animal-shaped sofa cushions in lazy, prone poses offer a healing touch. Filled with eco-friendly weighted glass beads, they provide a gentle hugging sensation, offering comfort and relaxation.

Emotional Comfort Across Categories

Emotional comfort was equally evident in products designed for children and pets.

A duck-shaped toy created for infants and toddlers aged 6 to 36 months attracted interest from overseas buyers. Simulating the movements of a real duck through head-turning and waddling motions alongside lights, sounds and voice guidance, the toy supports crawling, early learning and emotional comfort. Educational and bedtime-soothing modes offer music, stories, nursery rhymes and bilingual content, helping nurture development and providing a sense of security.

Meanwhile, the Pet Products and Food Section demonstrated how emotional needs also extend to animal companions. From creatively designed cat climbing structures to interactive automatic toys, exhibitors presented products aimed at enriching pets' daily lives and strengthening the bond between pets and their owners.

As consumers increasingly seek products that deliver emotional as well as practical benefits, Phase 3 of the 140th Canton Fair offers a glimpse into evolving lifestyles and expectations. The message behind "Better Life" is clear: better living is no longer defined solely by utility, but by products that bring comfort, connection and joy.

For more convenient attendance, please click here for pre-registration:

https://buyer.cantonfair.org.cn/register/buyer/email?source_type=16

SOURCE Canton Fair

Share this article

STAMFORD, Conn., Nov. 3, 2026 /PRNewswire/ -- Curaleaf Holdings, Inc. (TSX: CURA) (OTCQX: CURLF) ("Curaleaf"), a leading international provider of consumer and medical cannabis products, today acknowledges the announcement by Aurora Cannabis Inc. (TSX: ACB) (NASDAQ: ACB) ("Aurora") of an alternative transaction from Organigram Global Inc. ("Organigram").

Curaleaf's enhanced premium bid of October 6, 2026 to purchase all of the outstanding common shares of Aurora (the "Offer" or the "Curaleaf Offer") remains outstanding. Curaleaf believes its Offer represents better value, offering a superior combined business with a stronger capital markets profile, greater certainty and speed to close, and greater anticipated synergies. Curaleaf will study Organigram's alternative transaction and awaits disclosure of material details which have not been provided, including any break fee, management and board composition going forward, and any investor rights being granted to BAT. It is also revealing that neither Aurora nor Organigram made any reference to whether the transaction is dilutive or accretive to shareholders.

Aurora's board granted due diligence access to, in Curaleaf's view, a significantly smaller, underperforming and less liquid company, burdened with a looming share overhang, a history of, and forthcoming, shareholder dilution and weak cash generation, backed by an investor with its own disappointing cannabis investment track record. In Curaleaf's view, the refusal by Aurora's board to grant Curaleaf access and engage directly blocks any chance of an enhanced Curaleaf bid and constitutes gross dereliction of their fiduciary duties.

IMPORTANT INFORMATION

This document does not constitute an offer to buy or the solicitation of an offer to sell any securities. The Offer is made solely by the Offer to Purchase and Circular dated August 18, 2026, as amended on October 6, 2026 and as may be further amended or supplemented (the "Offer to Purchase and Circular").

SECURITY HOLDERS ARE URGED TO READ THE OFFER TO PURCHASE AND CIRCULAR, THE REGISTRATION STATEMENT ON FORM F-80, THE TENDER OFFER STATEMENT ON SCHEDULE 14D-1F, AND ALL OTHER RELEVANT DOCUMENTS FILED OR TO BE FILED WITH THE U.S. SECURITIES AND EXCHANGE COMMISSION (THE "SEC"), BECAUSE THEY CONTAIN IMPORTANT INFORMATION. Free copies are available at www.sec.gov or by contacting the Information Agent, Carson Proxy Advisors, at 1-800-530-5189 (toll-free), 416-751-2066 (local/text), or info@carsonproxy.com.

NOTICE TO U.S. SHAREHOLDERS

The enforcement by investors of civil liabilities under the federal securities laws may be affected adversely by the fact that the subject company is located in a foreign country, and that some or all of its officers and directors are residents of a foreign country.

Investors should be aware that the bidder or its affiliates, directly or indirectly, may bid for or make purchases of the issuer's securities subject to the offer or of the issuer's related securities, or of the bidder's securities to be distributed or of the bidder's related securities, during the period of the tender offer, as permitted by applicable Canadian laws or provincial laws or regulations.

Curaleaf has filed with the SEC a Registration Statement on Form F-80 under the U.S. Securities Act of 1933, as amended, and a Tender Offer Statement on Schedule 14D-1F under the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act"). The Offer is being conducted in accordance with Section 14(e) of the Exchange Act and Regulation 14E.

THE OFFER AND THE CURALEAF SUBORDINATE VOTING SHARES HAVE NOT BEEN APPROVED OR DISAPPROVED BY THE SEC OR ANY U.S. STATE SECURITIES COMMISSION, NOR HAS ANY SUCH AUTHORITY PASSED UPON THE ACCURACY OR ADEQUACY OF THIS DOCUMENT. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.

The Curaleaf subordinate voting shares issuable under the Offer have not been registered or otherwise qualified for offer and sale in certain U.S. states where shareholders may reside. No offer is made in those states except to qualifying Exempt Institutional Investors as described in the Offer to Purchase and Circular.

FORWARD-LOOKING STATEMENTS

This news release contains "forward-looking information" and "forward-looking statements" within the meaning of applicable Canadian and U.S. securities laws (together, "forward-looking statements"), including statements regarding the Offer, Curaleaf's review of the alternative transaction and Curaleaf's intentions with respect to the Offer and Aurora. Forward-looking statements can generally be identified by words such as "will," "intend," "expect," "believe," "may," "could" or similar expressions. Forward-looking statements are based on Curaleaf's current expectations and assumptions and are subject to known and unknown risks, uncertainties and other factors, many of which are beyond Curaleaf's control, that could cause actual results to differ materially, including the response of Aurora and its board of directors to the Offer, the terms and outcome of the competing proposal, the satisfaction or waiver of the conditions of the Offer, the receipt of regulatory approvals, and the other risks described in the Offer to Purchase and Circular and in Curaleaf's filings available at www.sedarplus.ca and www.sec.gov. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date of this news release. Curaleaf undertakes no obligation to update any forward-looking statements, except as required by applicable law.

AURORA AND ORGANIGRAM INFORMATION

Information concerning Aurora and Organigram herein is based solely on Aurora's and Organigram's publicly available filings and other public sources. Neither Aurora nor Organigram has not reviewed this document. Neither Curaleaf nor its officers or directors assume responsibility for the accuracy or completeness of such information.

About Curaleaf

Curaleaf is a leading international provider of consumer products in cannabis with a mission to enhance lives by cultivating, sharing and celebrating the power of the plant. As a high-growth cannabis company known for quality, expertise and reliability, Curaleaf and its brands, including Curaleaf, Select, Grassroots, Find, Dark Heart, and Anthem provide industry-leading service, product selection and accessibility across the medical and adult use markets. Curaleaf International is powered by a strong presence in all stages of the supply chain. Its unique distribution network throughout Europe, Canada and Australasia brings together pioneering science and research with cutting-edge cultivation, extraction and production. Curaleaf's subordinate voting shares are listed on the Toronto Stock Exchange under the symbol CURA and trade on the OTCQX market under the symbol CURLF. For more information, please visit https://ir.curaleaf.com.

Contacts

Media Contact

Kekst CNC

Kekst-Curaleaf@kekstcnc.com

Investor Contact

Curaleaf Holdings, Inc.

IR@curaleaf.com

Shareholder Contact 

Carson Proxy Advisors

North American Toll Free Phone: 1-800-530-5189

Local (Collect outside North America): 416-751-2066

Email: info@carsonproxy.com

SOURCE Curaleaf Holdings, Inc.

Share this article

TORONTO, Nov. 3, 2026 /PRNewswire/ -- Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic therapies for heart disease, is pleased to announce that it has entered into a sales agreement (the "ATM Agreement") with Jefferies LLC (the "Sales Agent") for an at-the-market offering program (the "ATM Program").

The ATM Agreement will allow the Company to offer and sell up to US$75 million of common shares of the Company (the "Offered Shares") under the ATM Program. The Offered Shares may be offered and sold by the Company to the public from time to time, through the Sales Agent. The Offered Shares sold under the ATM Program, if any, will be sold by means of ordinary brokers' transactions on the Nasdaq Capital Market (the "Nasdaq") or any other trading markets for the common shares in the United States at the prevailing market prices at the time of the sale. No Offered Shares will be offered or sold through the Toronto Stock Exchange or otherwise in Canada.

The sale of the Offered Shares through the ATM Program will be made pursuant to a prospectus supplement dated November 3, 2026 (the "Supplement") to the Company's Canadian final base shelf prospectus dated September 15, 2026 (the "Canadian Base Prospectus"), filed in each of the provinces and territories of Canada, and the Company's United States final base shelf prospectus dated September 15, 2026 (the "U.S. Base Prospectus" and together with the Canadian Base Prospectus, the "Base Prospectuses") forming a part of the Company's registration statement on Form F-10 (File No. 333-298852), as amended and effective upon filing on September 16, 2026 (the "Registration Statement", and collectively with the Supplement and Base Prospectuses, the "Offering Documents"), filed in the United States with the United States Securities and Exchange Commission (the "SEC"). As outlined in the Supplement, the Company intends to use the net proceeds of any such sales under the ATM Program to support the development of CardiolRx⢠for the treatment of recurrent pericarditis including, subject to the Phase III MAVERIC trial outcomes, supporting a New Drug Application, to support the clinical development of CRD-38 and for general and administrative expenses, working capital and other expenses.

The timing and extent of the use of the ATM Program will be at the discretion of the Company, and the Company has no obligation to sell any shares pursuant to the ATM Program. Accordingly, total gross proceeds from offerings under the ATM Program could be less than US$75 million. The ATM Program will be effective until the earliest of (i) the issuance and sale of all of the Offered Shares issuable pursuant to the ATM Program, (ii) the date that the ATM Program is terminated by Cardiol or the Sales Agent pursuant to the terms of the ATM Agreement, and (iii) the expiry of the Canadian Base Prospectus.

The Offering Documents contain important, detailed information about the ATM Program. The Supplement, accompanying Canadian Base Prospectus and ATM Agreement can be found on SEDAR+ at www.sedarplus.ca. The Supplement, Registration Statement (including the U.S. Base Prospectus) and the ATM Agreement can be found on EDGAR at www.sec.gov. Copies of the Supplement and the accompanying Base Prospectuses may also be obtained from Jefferies LLC, 520 Madison Avenue, New York, New York 10022, Attention: Equity Syndicate Prospectus Department, Phone: (877) 821-7388, Email: prospectus_department@jefferies.com. Prospective investors should read the Supplement and accompanying Base Prospectuses and the other documents the Company has filed before making an investment decision.

The Toronto Stock Exchange has conditionally approved the ATM Program and the Nasdaq has been notified of the ATM Program.

This news release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.

About Cardiol Therapeutics

Cardiol Therapeutics Inc. is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease.

Cautionary statement regarding forward-looking information:

This news release contains "forward-looking information" or "forward-looking statements" within the meaning of applicable securities laws (referred to here as "forward-looking information"). All statements, other than statements of historical fact, that address activities, events, or developments that Cardiol believes, expects, or anticipates will, may, could, or might occur in the future are "forward-looking information". Forward looking information contained herein may include, but is not limited to statements regarding the ATM Program, the timing and extent of the use of the ATM Program, that Offered Shares under the ATM Program will be sold on the Nasdaq, when the ATM Program will be effective and the use of proceeds from sales made under the ATM Program. Forward-looking information contained herein reflects the current expectations or beliefs of Cardiol based on information currently available to it and is based on certain assumptions and is also subject to a variety of known and unknown risks and uncertainties and other factors that could cause the actual events or results to differ materially from any future results, performance or achievements expressed or implied by the forward looking information, and are not (and should not be considered to be) guarantees of future performance. These risks and uncertainties and other factors include the risks and uncertainties referred to in the Company's Annual Information Form filed with the Canadian securities administrators and the SEC (as part of its Annual Report on Form 40-F) on March 31, 2026, available on SEDAR+ at sedarplus.ca and EDGAR at sec.gov, respectively, as well as the risks and uncertainties associated with product commercialization and clinical studies, including the timing and outcomes of the Phase III MAVERIC trial and any related regulatory submissions. These assumptions, risks, uncertainties, and other factors should be considered carefully, and investors should not place undue reliance on the forward-looking information, and such information may not be appropriate for other purposes. Any forward-looking information speaks only as of the date of this press release and, except as may be required by applicable securities laws, Cardiol disclaims any intent or obligation to update or revise such forward-looking information, whether as a result of new information, future events, or results, or otherwise. Investors are cautioned not to rely on this forward-looking information and are encouraged to read the Supplement, the accompanying Base Prospectuses and the documents incorporated by reference therein.

SOURCE Cardiol Therapeutics Inc.

Share this article

H.E. Ahmed Al-Khateeb, Saudi Minister of Tourism, Inaugurates Saudi Land at WTM London 2026, Reinforcing Saudi's Commitment to Global Travel Trade

- 37 Saudi tourism partners connect with international travel buyers to showcase new destinations, experiences and opportunities for winter and beyond.

- Saudi celebrates its newest luxury destination, AMAALA, in partnership with Red Sea Global.

LONDON, Nov. 3, 2026 /PRNewswire/ -- His Excellency Ahmed Al-Khateeb, Minister of Tourism and Chairman of the Board of Directors of the Saudi Tourism Authority (STA), officially inaugurated Saudi Land at World Travel Market (WTM) London 2026, alongside Ageel Alshaibani, CEO of STA, and Rachel Travers, President of the RX Global, organizer of WTM London, bringing together 37 Saudi tourism partners to showcase the country's expanding tourism offering and strengthen commercial partnerships with the global travel trade.

Over the three-day event, Saudi's delegation will engage international tour operators, airlines and travel distributors, introducing new products and experiences across destinations including Riyadh, Jeddah, AlUla, the Red Sea, and AMAALA, while creating opportunities to drive demand for the upcoming winter season and beyond.

His Excellency Ahmed Al-Khateeb, Saudi Minister of Tourism and Chairman of the Board of Directors of the Saudi Tourism Authority, said: "Resilience is built before you need it, and this year Saudi tourism has demonstrated the strength of its foundations. In the first half of 2026, Saudi welcomed about 61.2 million tourist, representing about 1% growth year-on-year, while tourism expenditure reached about SAR 151.9 billion (approximately $40.5 billion). We know the pressures our partners and travelers have faced, and our commitment to them is long term, as we work towards our ambition of welcoming 150 million tourists by 2030. No destination builds that kind of resilience alone, so we will continue bringing the industry together, here in London and through TOURISE, the global, year-round platform shaping the future of tourism."

Ageel Alshaibani, CEO of STA, added: "Our trade partners have been instrumental in Saudi tourism's growth, and their success remains our priority. At WTM London, we are showcasing Red Sea escapes, desert experiences and a winter calendar featuring Riyadh Season and Winter at Tantora in AlUla, alongside attractions such as Six Flags Qiddiya City and Aquarabia. These experiences are backed by continued hospitality investment, with about 623K licensed room keys across hotels, apartments and other accommodation in H1 2026, including more than 44K room keys in newly licensed facilities. We are here to create opportunities and grow together."

Saudi Land celebrated AMAALA, one of Saudi's newest luxury coastal destinations, as a key highlight of its opening day, showcasing the destination's growing hospitality offering to international travel partners. Since June, seven resorts, including properties from Four Seasons, Six Senses, Rosewood and Nammos, have welcomed guests, further strengthening AMAALA's position as a distinctive luxury destination and adding to Saudi's expanding portfolio of high-end tourism experiences.

Saudi Land also brings the country's cultural heritage to life throughout the event, with traditional music and dance, Arabic calligraphy and interactive experiences inspired by destinations across Saudi Arabia.

Saudi Land will remain open at stand S9-200 at ExCeL London until 5 November, with 37 tourism partners engaging international buyers, developing new partnerships and creating commercial opportunities for the future.

SOURCE Saudi Tourism Authority

Share this article

Mineral Resource update includes maiden estimates at the Helios Caesium Zone and CV4 Pegmatite, contributing to overall resource growth in all three critical minerals (Li, Cs, Ta) at the Shaakichiuwaanaan Property

MONTREAL, Nov. 3, 2026 /PRNewswire/ -- November 4, 2026 â Sydney, Australia

Significant increase in contained caesium metal (55%), grade (31%), and tonnage (18%) of the Caesium Zone MRE1, inclusive of the Vega, Rigel, and newly estimated Helios Zones.

1,844,000 t at 4.40% Cs2O (Indicated) â 81,200 t Cs2O in contained metal.

981,000 t at 3.00% Cs2O (Inferred) â 29,400 t Cs2O in contained metal.

Already the world's largest pollucite (caesium) pegmatite, this MRE has further increased contained metal from 71,000 t to 110,600 t Cs2O.

Additional critical mineral added to resource base with maiden rubidium (Rb) resources declared within the Caesium Zone MRE at a grade of 0.46% Rb2O (Indicated) and 0.37% Rb2O (Inferred). Rubidium is a soft, silvery-white alkali metal used primarily in scientific research, precision timekeeping, and specialized technologies.

Consolidated MRE at Shaakichiuwaanaan confirms over 40 Mt of greater than 2% Li2O grade at CV5 and CV13 combined (indicated).

Sensitivity analysis outlines very high-grade (Li) subsets of the resource at significant tonnage, primarily reflecting the Nova (CV5) and Vega (CV13) Zones, respectively (at 1.5% Li2O cut-off):

36.5 Mt at 2.04% Li2O (Indicated), 4.1Mt at 2.01% Li2O (Inferred).

5.9 Mt at 2.77% Li2O (Indicated), 4.2Mt at 2.24% Li2O (Inferred).

113.9 Mt at 1.43% Li2O and 164 ppm Ta2O5 (Indicated) â 4.03 Mt LCE.

33.8 Mt at 1.24% Li2O and 150 ppm Ta2O5 (Inferred) â 1.03 Mt LCE.

MRE continues to re-affirm Shaakichiuwaanaan as one of the largest and highest-grade tantalum pegmatites globally.

Increase in contained LCE2 (5%) driven by combined impact of improved tonnage (4%) and grade (0.2%) of consolidated MRE at Shaakichiuwaanaan3:

A total of 87.4 Mt (Indicated) and 2.2 Mt (Inferred) is contained within a single dyke at the CV5 Pegmatite, which is anticipated to significantly limit external dilution and simplify mining.

Includes 1.75 Mt at 1.24% Li2O (Inferred) maiden resource at the CV4 Pegmatite, approximately 1.5 km along strike and to the east of CV5, with the gap between offering further exploration potential for additional resource growth (more drilling required).

MRE4 update announced herein to underpin an updated Feasibility Study for Li and Ta on the CV5 Pegmatite and a Preliminary Economic Assessment for Li, Cs, and Ta on the broader Project (CV5 & CV13 Pegmatites), on schedule to be announced before year end.

Darren L. Smith â Executive Vice President of Exploration commented: "Although the 2025 drill program focused on development objectives for the Project, the work has also grown the overall resource base for all three metals, highlighted by the significant increases in the Caesium Zone MRE grade, tonnage, and contained metal.

"Shaakichiuwaanaan continues to demonstrate considerable scale in lithium, caesium, and tantalum inclusive of very high-grade subsets of the resource. Given the size of the overall resource, it is easy to forget that the scale and grade of the Nova and Vega Zones are globally significant in their own right. This is an important part of what makes the Project so unique. We are very confident there is a lot more to discover as we expand our exploration focus in future programs," added Mr. Smith.

PMET RESOURCES INC. (THE "COMPANY" OR "PMET") (TSX: PMET) (ASX: PMT) (OTCQX: PMETF) (FSE: R9GA) is pleased to announce an updated Consolidated Mineral Resource Estimate ("Consolidated MRE") for its 100%-owned Shaakichiuwaanaan Property (the "Property" or "Project") located in the Eeyou Istchee James Bay region of Quebec. The Consolidated MRE, the fifth to date for the Project ("MRE-5"), includes the CV5, CV13, and CV4 lithium-caesium-tantalum ("LCT") pegmatites and is accessible by all-season road, proximal to regional hydropower infrastructure (Figure 2 and Figure 14).

In addition to continued growth in the lithium-tantalum consolidated resource base (see below), MRE-55 has resulted in a significant increase in caesium ("Cs") resources both in terms of grade (31%), tonnage (18%), and contained metal (55%) inclusive of the Vega, Rigel, and newly estimated Helios zones (all within the CV13 Pegmatite) â 1,844,000 t at 4.40% Cs2O (Indicated) and 981,000 t at 3.00% Cs2O (Inferred) for a contained caesium content (Cs2O) of 81,200 t and 29,400 t, respectively (Table 2). This reaffirms Shaakichiuwaanaan's position as hosting the world's largest pollucite (caesium) pegmatite MRE (Figure 1).

The scale of Shaakichiuwaanaan's caesium resource is particularly significant given the supply-constrained nature of the global caesium market. Caesium formate is a premium high-density drilling fluid used in high-pressure, high-temperature (HPHT) oil and gas wells, particularly in the North Sea, with potential for broader adoption in offshore basins such as Brazil, the Gulf of Mexico, and Southeast Asia. Historically limited and highly concentrated supply has constrained wider market adoption. The emergence of a large-scale, reliable North American source of caesium could not only diversify global supply chains, but also enable the development of new caesium formate inventory pools, supporting expanded offshore exploration and greater energy security.

Additionally, a maiden rubidium ("Rb") Mineral Resource has been declared within the Caesium Zone MRE at a grade of 0.46% Rb2O (Indicated) and 0.37% Rb2O (Inferred). The target mineral for recovery for both Cs and rubidium Rb is pollucite, which is the primary host to Cs at Shaakichiuwaanaan and is the preferred source mineral for Cs globally.

The updated Consolidated MRE demonstrates continued growth in the overall resource base with increases in lithium grade (0.2%), tonnage (4%), and contained metal (5%). This includes tonnage increases at both CV5 (1.6%) and CV13 (10.4%) (Table 1):

113.9 Mt at 1.43% Li2O and 164 ppm Ta2O5 (Indicated) â 4.03 Mt LCE and 18.7 kt Ta2O5 contained, respectively.

33.8 Mt at 1.24% Li2O and 150 ppm Ta2O5 (Inferred) â 1.03 Mt LCE and 5.1 kt Ta2O5 contained, respectively.

Shaakichiuwaanaan continues to host one of the world's largest and highest-grade tantalum pegmatite MREs. Coupled with the scale and grade of the lithium and caesium resources, the tantalum provides another key differentiator for the Project.

A total of 87.4 Mt (Indicated) and 2.2 Mt (Inferred) is contained within a single principal dyke at the CV5 Pegmatite, which extends nearly 5 km in length at true widths of up to ~125 m. The scale of the resources within this single, broad dyke is significant as it is anticipated to reduce external dilution, simplify the overall mining approach, and reduce the mineral processing risk.

Additionally, MRE-5 includes maiden resources at the CV4 Pegmatite totaling 1.75 Mt at 1.24% Li2O (Inferred) and is interpreted to represent a potential 1.5 km extension of the principal CV5 Pegmatite dyke. This gap (CV5 to CV4) represents a key exploration area for future resource growth.

HIGH-GRADE NOVA AND VEGA ZONES ARE KEY DIFFERENTIATORS

The relatively high-grade nature of the Shaakichiuwaanaan MRE, highlighted by the Nova (CV5) and Vega (CV13) Zones, is a key and powerful differentiator for the Company (Figure 5). In the MRE-5 sensitivity analysis (Table 3), significant tonnage is outlined at very high-grade (>2.00% Li2O), primarily reflecting these two zones, respectively (at 1.5% Li2O cut-off):

36.5 Mt at 2.04% Li2O (Indicated), 4.1Mt at 2.01% Li2O (Inferred).

5.9 Mt at 2.77% Li2O (Indicated), 4.2Mt at 2.24% Li2O (Inferred).

These zones of intense spodumene mineralization at scale (both with 10+ m drill intervals at >5% Li2O) are exceedingly rare â and potentially unique â in LCT pegmatite deposits known globally. Such scale and grade offer the opportunity to have higher-margin tonnes (potentially relatively early in the mine-life), improved recoveries, and backstop a highly robust production profile that can withstand significant downturn in the markets over prolonged periods. Collectively, these attributes lend Shaakichiuwaanaan a very defensible nature to market nuance, which is anticipated to be outlined in further detail within the updated Feasibility Study at CV5 and Preliminary Economic Assessment on the broader project (CV5 & CV13) scheduled to be announced before year end.

NEXT STEPS

MRE-5 â which includes drilling through to the end 2025 â is intended to underpin an updated Feasibility Study for Li and Ta on the CV5 Pegmatite and a Preliminary Economic Assessment for Li, Cs, and Ta on the broader Project (CV5 & CV13 Pegmatites), on schedule to be announced before year end. Drilling completed in 2026 will be incorporated into a future MRE update for the Project, anticipated in 2027.

MINERAL RESOURCE STATEMENT (NI 43-101) â MRE-5

Table 1: Consolidated Mineral Resource Statement for the Shaakichiuwaanaan Project.

Table 2: Caesium Zone Mineral Resources within the CV13 Pegmatite.

Mineral Resources were prepared in accordance with National Instrument 43-101 â Standards for Disclosure for Mineral Projects ("NI 43-101"), the CIM Definition Standards (2014) and the JORC Code (2012). Mineral Resources that are not Mineral Reserves do not have demonstrated economic viability. This estimate of Mineral Resources may be materially affected by environmental, permitting, legal, title, taxation, sociopolitical, marketing, economic, or other relevant issues.

The independent Competent Person (CP), as defined under JORC, and Qualified Person (QP), as defined by NI 43â101 for this resource estimate is Todd McCracken, P.Geo., Director â Mining & Geology â Central Canada, BBA Consultants. The Effective Date of the estimate is July 10, 2026 (through drill hole CV25-1025).

BATON ROUGE, La., Nov. 3, 2026 /PRNewswire/ -- APTIM ("APTIM" or the "Company"), a leading environmental and resilience consulting firm with a long history of providing expertise and integrated solutions to government and commercial customers, today announced that Chuck Prow has been appointed Chief Executive Officer and Chairman, effective November 9, 2026. He succeeds Mark Fallon, who will step down from the roles of CEO and Chairman to pursue other ventures.

Prow brings over three decades of experience leading global enterprises and deep expertise in critical infrastructure and growth strategy. Most recently, he served as CEO of V2X, a leading defense infrastructure management and technology firm with more than $4.0 billion in revenues. Prow led the formation of V2X following the merger of The Vertex Company with Vectrus, where he served as CEO since 2017. He is a 10-time Wash100 Award winner, has served on multiple boards in the government technology market, and previously held executive leadership roles in the government and public sector businesses of IBM and PwC. At APTIM, Prow will partner closely with Jon Grant, Chief Financial Officer, and the leadership team to strengthen the Company's position as a premier government services provider.

"At a time of rapid infrastructure change, the need for APTIM's specialized services is more acute than ever, and I'm thrilled to step into the role of CEO at such an exciting moment for the Company," said Prow. "With an exceptional team, deep technical expertise, and longstanding customer relationships, I believe APTIM is positioned to capitalize on growing investment in defense modernization, energy security, and critical infrastructure. I look forward to working alongside Jon and the broader team to build on this strong foundation and capture the significant opportunities ahead of us."

"I'm grateful for the privilege of working alongside so many committed and talented teammates at APTIM," said Fallon. "I am so proud of the work that we have done together and all that APTIM will continue to do to deliver on the most challenging environmental and infrastructure missions for clients."

About APTIM

APTIM enhances the quality of the environment, wellbeing of people, resilience of communities, and opportunity for employees to make a difference, not just a living. A leading professional solutions firm, we specialize in environmental, sustainability, resilience, and infrastructure solutions. Our team of experts provides these integrated solutions for forward-thinking government agencies, commercial and industrial clients, and energy customers. Together, we create sustainable and resilient communities for all. Learn more at APTIM.com, and connect with us on LinkedIn, Facebook, Instagram, and X.

SOURCE APTIM

Share this article

Direct Connection Unleashes New Series of HEMI® V8 Crate Engine Packages

LAS VEGAS, Nov. 3, 2026 /PRNewswire/ --

- New program combines legendary HEMI® V8 performance, engine controller integration and Direct Connection exclusivity in one complete turnkey package geared toward both manual and automatic transmission applications

- All-new Direct Connection crate engine packages with controller kit are backed by three-year / 100,000-mile warranty

- Six new crate engine package options offer horsepower ranging from 385 horsepower to 1,025 horsepower with flex fuel capability

- New exclusive and branded shipping crates celebrate the heritage and performance legacy of SRT and Direct Connection

- Direct Connection crate engine packages will be available starting in the first quarter of 2027; final production content may vary by package, pricing to be announced

Direct Connection, the official factory-backed performance parts arm of Stellantis' SRT Performance division, unveils an all-new series of crate engine packages at the 2026 SEMA Show, delivering a new lineup of turnkey solutions engineered to simplify builds and maximize performance for enthusiast builders, racers and restoration specialists.

Every new engine package combines a Direct Connection crate engine and matching controller kit into a single, coordinated offering designed to put projects on the road faster and with greater efficiency. The series also introduces exclusive Direct Connection branding, serialized engine identification plaques and premium branded crate packaging.

"Our philosophy is simple: one part, one solution. If you're going to build something serious, you shouldn't have to guess whether all the pieces are going to work together," said Tim Kuniskis, head of American Brands, SRT Performance and Direct Connection division, Stellantis North America. "That's what these new Direct Connection crate engine packages are about. Everything you need, engineered to work together, in one turnkey package. Whether you're bringing a classic muscle car back to life or building something for the street or the track, we're making it easier to get the performance you want and the confidence that comes with it."

Expanding Product Lineup: Six New Packages With Manual and Automatic Transmission Options

345 Crate HEMI® Engine Package - Street Strip

(automatic P/N: DC345000AA, manual P/N: DC345010AA)

- 345-cubic-inch displacement

- 385 horsepower and 417 lb-ft torque

- Remanufactured performance engine block: cast iron with four-bolt powder metal caps

- Bore: 95mm

- Stroke: 90.9mm

- Crank material: nodular iron

- Connecting rods: floating pin powdered metal

- 319 aluminum HEMIspherical combustion cylinder heads

- Valve sizes:

- Intake: 52.1mm

- Exhaust: 39.4mm

- Compression ratio: 10.5:1

- NEW unique black valve covers with raised Direct Connection branding

- Recommended automatic application: TorqueFlite 8HP90 automatic transmission kit (P/N: PW100075AA)

- Recommended manual application: TREMEC Magnum (P/N: PW100004)

New Direct Connection 345 Street Strip Crate Engine Package includes:

- Crate engine wiring / Power Distribution Center (PDC) kit

- Flashed powertrain control module (PCM)

- O2 sensors

- Accelerator pedal

- Shifter (automatic only)

- Brake press switch (automatic only)

- Direct Connection branded crate

- Fender tag with unique serialization and engine specifications

345 Crate HEMI Engine Package - Super Stock

(automatic P/N: DC345001AA, manual P/N: DC345011AA)

- 345-cubic-inch displacement

- 385 horsepower and 417 lb-ft torque

- New performance block: cast iron with four-bolt powder metal caps

- Bore: 95mm

- Stroke: 90.9mm

- Crank material: nodular iron

- Connecting rods: floating pin powdered metal

- 319 aluminum HEMIspherical combustion cylinder heads

- Valve sizes:

- Intake: 52.1mm

- Exhaust: 39.4mm

- Compression ratio: 10.5:1

- NEW unique black valve covers with raised Direct Connection branding

- Recommended automatic application: TorqueFlite 8HP90 automatic transmission kit (P/N: PW100075AA)

- Recommended manual application: TREMEC Magnum (P/N: PW100004)

345 Super Stock upgrades:

- Redeye Valve Springs: Provides enhanced valvetrain control for improved high-RPM performance

- SRT Hellcat Oil Pump: Provides upgraded oiling capacity for improved lubrication

- Larger SRT Oil Filter: Provides increased filtration capacity

- SRT Oil Cooler: Provides improved oil temperature control during sustained high-load operation

New Direct Connection 345 Super Stock Crate Engine Package includes:

- Crate engine wiring / power distribution center (PDC) kit

- Flashed powertrain control module (PCM)

- O2 sensors

- Accelerator pedal

- Shifter (automatic only)

- Brake press switch (automatic only)

- Direct Connection branded crate

- Fender tag with unique serialization and engine specifications

392 Crate HEMI Engine Package - Street Strip

(automatic P/N: DC392000AA, manual P/N: DC392010AA)

- 392-cubic-inch displacement

- 485 horsepower and 475 lb-ft torque

- Remanufactured performance block: cast iron with 4-bolt powder metal caps

- Bore: 103.9mm

- Stroke: 94.6mm

- Crank material: forged steel

- Connecting rods: floating pin powdered metal

- 319 aluminum HEMIspherical combustion cylinder heads

- Valve sizes:

- Intake: 54.3mm

- Exhaust: 42mm

- Compression ratio: 10.9:1

- Peak RPM: 6,400

- NEW HEMI orange valve covers with raised Direct Connection branding

- Recommended automatic application: TorqueFlite 8HP90 automatic transmission kit (P/N: PW100076AA)

- Recommended manual application: TREMEC Magnum (P/N: PW100004)

New Direct Connection 392 Street Strip Crate Engine Package includes:

- Crate engine wiring / power distribution center (PDC) kit

- Flashed powertrain control module (PCM)

- O2 sensors

- Accelerator pedal

- Shifter (automatic only)

- Brake press switch (automatic only)

- Direct Connection branded crate

- Fender tag with unique serialization and engine specifications

392 Crate HEMI Engine Package - Super Stock

(automatic P/N: DC392001AA, manual P/N: DC392011AA)

- 392-cubic-inch displacement

- 485 horsepower and 475 lb-ft torque

- New performance block: cast iron with 4-bolt powder metal caps

- Bore: 103.9mm

- Stroke: 94.6mm

- Crank material: forged Steel

- Connecting rods: floating pin powdered metal

- 319 aluminum HEMIspherical combustion cylinder heads

- Valve sizes:

- Intake: 54.3mm

- Exhaust: 42mm

- Compression ratio: 10.9:1

- Peak RPM: 6,400

- New HEMI orange valve covers with raised Direct Connection branding

- Recommended automatic application: TorqueFlite 8HP90 automatic transmission kit (P/N: PW100076AA)

- Recommended manual application: TREMEC Magnum (P/N: PW100004)

392 Super Stock upgrades:

- Redeye Valve Springs: Provide enhanced valvetrain control for improved high-RPM performance

- SRT Hellcat Oil Pump: Provides upgraded oiling capacity for improved lubrication

- SRT Oil Cooler: Provides improved oil temperature control during sustained high-load operation

New Direct Connection 392 Super Stock Crate Engine Package includes:

- Crate engine wiring / power distribution center (PDC) kit

- Flashed powertrain control module (PCM)

- O2 sensors

- Accelerator pedal

- Shifter (automatic only)

- Brake press switch (automatic only)

- Direct Connection branded crate

- Fender tag with unique serialization and engine specifications

Hellcrate Redeye 6.2L Supercharged Crate HEMI Engine Package - Super Stock

(automatic P/N: DC376101AA, manual P/N: DC376111AA)

- 376-cubic-inch displacement

- Up to 885 horsepower and 787 lb-ft of torque in High Octane Mode

- 2.7L IHI twin screw supercharger

- Performance block: cast iron with 4-bolt powder metal caps

- Bore: 103.9mm

- Stroke: 90.9mm

- Crank material: forged alloy steel

- Connecting rods: forged powdered metal steel with diamond-like coating wrist pins

- Cylinder heads: 356 aluminum HEMIspherical combustion chamber cylinder heads

- Valve sizes:

- Intake: 54.3mm

- Exhaust: 42mm

- Compression ratio: 9.5:1

- Peak RPM: 6,500

- NEW unique red valve covers with raised Direct Connection branding

- Required automatic application: TorqueFlite 8HP90 automatic transmission kit (P/N: PW100074AA)

- Recommended manual application: TREMEC Magnum (P/N: PW100004)

New Direct Connection Redeye 6.2L Supercharged Super Stock Crate Engine Package includes:

- Crate engine wiring / power distribution center (PDC) kit

- Flashed powertrain control module (PCM)

- O2 sensors

- Accelerator pedal

- Shifter (automatic only)

- Brake press switch (automatic only)

- Hellephant 426 supercharger pulley

- 180-degree performance thermostat

- Direct Connection branded crate

- Fender tag with unique serialization and engine specifications

Hellephant C170 6.2L Supercharged Crate HEMI Engine Package - Super Stock

(automatic P/N: DC376201AA, manual P/N: DC376211AA)

- 376-cubic-inch displacement

- Capable of 1,025 horsepower and 945 lb-ft torque on E85 blend

- 3.0L IHI Supercharger with improved intercooler and larger snout

- 3.02-inch pulley for increased boost

- 105mm throttle body

- Ethanol sensor and upgraded fuel rail and injectors for improved fuel flow to support E85 fuel

- Upgraded pistons with top land cutback to improve combustion sealing

- Billet steel main caps for improved strength

- Performance block: cast iron with 4-bolt billet steel main caps

- Bore: 103.9mm

- Stroke: 90.9mm

- Crank material: forged alloy steel

- Connecting rods: forged powdered metal steel with diamond-like coating wrist pins

- 356 aluminum HEMIspherical combustion cylinder heads

- Valve sizes:

- Intake: 54.3mm

- Exhaust: 42mm

- Compression ratio: 9.5:1

- Peak RPM: 6,500

- NEW unique yellow valve covers with raised Direct Connection branding

- Required automatic application: TorqueFlite 8HP90 automatic transmission kit (P/N: PW100067AB)

- Recommended manual application: TREMEC Magnum (P/N: PW100004)

New Direct Connection Hellephant C170 6.